Loading
Xaluritamig is Amgen's T-cell engager for prostate cancer, now in two phase 3 trials, aiming to do for prostate cancer what tarlatamab did for small-cell lung cancer.
Phase 1 (ESMO 2024): PSA50 ~49% and confirmed responses in heavily pretreated mCRPC at high doses; CRS mostly grade 1-2 with step-up dosing. XALute (NCT06691984, n≈675, post-taxane, vs cabazitaxel or ARPI, OS primary; active, not recruiting) and XALience (with abiraterone, chemo-naive mCRPC).
Backbone ribbon from PDB 8UCD. RCSB PDB 8UCD. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Two STEAP1-binding domains and one CD3 arm (avidity for high-STEAP1 cells) redirect T cells. Connects to STEAP1 and CD3.
1.One arm of Xaluritamig binds STEAP1 on the cancer cell.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Xaluritamig" OR ABSTRACT:"Xaluritamig" OR TITLE:"AMG 509" OR ABSTRACT:"AMG 509") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Xaluritamig, not a curated reading list.
Shares CD3, Cytokine release syndrome (CRS), T-cell engagers (bispecific), Metastatic castration-resistant prostate cancer.
Shares CD3, T-cell engagers (bispecific), Prostate cancer.
Shares STEAP1, Prostate cancer.
Shares CD3, Amgen, T-cell engagers (bispecific).
Shares XALute, A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate , Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares PSA50 / PSA90 response, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares T-cell engagers (bispecific), Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Amgen, T-cell engagers (bispecific).